» New drugs bring hope to ALS patients
» Chosa Oncology gets green light for patent in China
» Gabather's aims to impact the neurodegeneration field
» Progress with new gene therapy for serious skin disease
» Klaria continues to take steps towards market approval
Read BioStock's newsletter for v. 50 here.
On November 29-30, BioStock Life Science Summit held at Medicon Village in Lund. All presentations from the event are now available via the banner below!
Morning news
Chordate Medical invites you to a live investor meeting on December 29th. Read more.
Sedana Medical receives a positive opinion from EMAs Pediatric Committee regarding reduced pediatric study design. Read more.
Coala-Life Group plans to carry out a rights issue of units. Read more.
Bavarian Nordic contracts worth up to 83 million USD are signed with the US Department of Defense. Read more.
XP Chemistries announces that they have delivered two larger orders. Read more.
Initiator Pharma decides not to exercise the option on a drug candidate in an unannounced pain indication. Read more.
BioArctics Partner Eisai begins submitting the registration application for lecanemab in China. Read more.
The board of directors Lipidor calls an extraordinary general meeting to approve the sale of subsidiary shares to major owners. Read more.
Affibody a loan agreement of EUR 20 million is signed with European Investment Bank. Read more.
Financial calendars:
News since Thursday lunch
Emplicure announced results from the exploratory clinical pharmacokinetic study on its drug candidate Empli03. Read more.
AlzeCure published the outcome of the oversubscribed rights issue. Read more.
Klaria Pharma published the results of its new share issue. Read more.
Acarix published supplementary prospectus. Read more.
Gradientech announced that it is carrying out a rights issue of approximately SEK 50 million. Read more.
Aptahem published newsletter for December 2022. Read more.
AegirBio announced that Nasdaq Stockholm has decided to submit the ongoing investigation case to the disciplinary committee with a request for delisting. Read more.
Bioactive Bone Substitutes visited the Finnish Parliament. Read more.
SensoDetect published results from medication study. Read more.
Bavarian Nordic has completed enrollment in the global Phase III trial of RSV vaccine candidate for older adults. Read more.
Nykode Therapeutics announced that the share capital of the company has increased. Read more.
Lumito has recruited a new quality manager. Read more.
BactiQuant announced goals and guidance for 2023. Read more.
This morning's price development
Winner: Diagonal Cinema 54,3%, RhoVac 39,1%, Double Bond Pharmaceutical 23,4%, Lipidor 19,4%, Neola Medical 14,9%
Förlorare: Aegirbio -56,5%, Coala-life Group 42,7%, Emplicure -13,3%, Aptahem -9,3%, SenzaGen -7,2%
Index: OMXS30 2 055%, Healthcare 0,58%
More from BioStock
» Chordate's CEO on financing and future plans
» Idogen strengthens fund for clinical study in 2023
» Chordate: “We are putting pretty much everything into the market”
» Alzinova on the interim results and the now fully recruited phase Ib study
» Thomas Eldered on Xintela's progress